In its recent earnings call, CooperVision and CooperSurgical reported record quarterly revenues, driven by silicone hydrogel lenses, myopia management, fertility, and PARAGARD. Consolidated revenues reached $720 million, up 32%. CooperVision saw a 25% increase in revenues, primarily due to growth in silicone hydrogel dailies and FRP products, including Biofinity. CooperSurgical posted a 58% revenue increase, driven by strength in fertility and office and surgical medical devices. Myopia management grew significantly at 122%, with MiSight growing 152% and Ortho K 112%. The company is expanding its myopia management portfolio and expects it to exceed $100 million in sales next year. PARAGARD, a hormone-free contraceptive, contributed significantly to CooperSurgical's growth. Despite COVID-19 challenges, the company remains optimistic about long-term growth, supported by favorable market trends and the rollout of vaccines. Non-GAAP earnings per share were $3.38, with a guidance range of $13.20 to $13.40 for fiscal 2021.